Two global drug manufacturers, Pfizer and Cipla, have signed a deal that will see Kenyans buy a range of up to 16 cancer drugs at half the market price.
The partnership is backed by the American Cancer Society (ACS) and Clinton Health Access Initiative (CHAI).
The deal will see an increase in access to life-saving cancer treatment including chemotherapies in five other African countries; Ethiopia, Nigeria Uganda, Rwanda and Tanzania.
Pfizer will provide 11 branded cancer medicines namely; Carboplatin, Cisplatin, Docetaxel, Doxorubicin, Epirubicin, Fluorouracil, Gemcitabine, Leucovorin, Methotrexate, Oxaliplatin, and Paclitaxel.
The agreement with Cipla covers Anastrazole, Bleomycin, Capecitabine, Carboplatin, Cisplatin, Cytarabine, Oxaliplatin and Vinblastine.
“Every person with cancer deserves access to treatment, no matter where they live. Collaborating with companies like Pfizer and Cipla is a critical next step toward leveling the playing field for people with cancer and saving lives in this part of the world,” said ACS chief executive, Gary M Reedy. Read the full article